The treatment of patients with bladder cancer has recently seen an evolution with the FDA approval of immune checkpoint inhibitors. Prior to this new therapy, for over 25 years, bladder cancer care had few breakthrough advancements. With the advent of new technologies associated both with surgical technique and better understanding of the biology of this disease we come to an exciting era in understanding and treating patients with bladder cancer.

Key Leaders’ Opinion on Novel Progress in Diagnosis and Treatment of Bladder Cancer is a collection of recently published papers by international experts in the field of bladder cancer. This series highlights the advancements in the molecular biology, surgical technique and novel therapeutic options for patients with bladder cancer. Furthermore, this series highlights the importance of a multi-disciplinary approach to treating patients with bladder cancer. In this series you will find highlights associated with systemic therapy, surgical care as well as nursing care.

Specifically, you will find six sections each summarizing the recent important contributions to bladder cancer by my esteemed colleagues. The Precision Medicine for Individualized Therapy section discusses the evolution in understanding the molecular biology and genetics of both non-muscle and muscle invasive bladder cancer. This section identifies the most recent genetics in bladder cancer, which can be used to help us to better understand the machinery that drives this disease and to identify biomarkers to better risk stratification our patients. Novel Advances in Surgical Technology and Debates and Experience in Traditional Surgical Treatment discuss the innovations in surgical techniques and how their use has improved the morbidity associated with surgical care of bladder cancer patients. The sections; Progress in Chemotherapy and Medical Treatment and Fresh Vision of Pathogenesis and Development and Prognosis summarizes recent improvements on how we should approach treating bladder cancer patients. Lastly, and in my opinion the most important section, Experience and Exploration in Clinical Nursing, highlights the importance of a multi-disciplinary approach to treating bladder cancer patients.

This is a very comprehensive and exciting series that summarizes the current excitement in the field of bladder cancer. It is an honor to write the preface for this book. It is a collaboration of many colleagues with a similar interest in advancing the field of bladder cancer. This book is a great summary of the important research being performed in the field and how bright the future is for improving treatment for our bladder cancer patients. I hope everyone enjoys the read.

John P. Sfakianos

John P. Sfakianos, MD
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA